Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
This article was originally published in The Pink Sheet Daily
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.
You may also be interested in...
FDA’s most recent accelerated approvals for Merck’s Keytruda call for confirmatory trials in a broader patient population than the approved indications, in the latest example of FDA’s growing comfort with multi-purpose confirmatory trials in the PD-1/PD-L1 inhibitor space.
The company is starting to explore triple immuno-oncology combinations, Head of Oncology-Global Clinical Research Jean Viallet said, but IO development is mainly focused on expanding the firm's existing double combination, Opdivo and Yervoy, to earlier treatment and new tumors.
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.